Risk adjusted net present value: What is the current valuation of Vigil Neuroscience’s Iluzanebart?

Iluzanebart is a monoclonal antibody commercialized by Vigil Neuroscience, with a leading Phase III program in Neurodegenerative Diseases.

Pulse oximeters’ inaccuracies in darker-skinned people require urgent action, AGs tell FDA

More than two dozen attorneys general are urging Food and Drug Administration officials to take urgent action to address disparities in how well pulse oximeters,

November 7, 2023

Kidney disease therapy Jardiance gains FDA approval

Jardiance is intended to treat chronic kidney disease. Credit: Pixel-Shot / Shutterstock.com. Boehringer Ingelheim and Eli Lilly and Company have received approval from the US

September 25, 2023

Lindis Blood Care Announces Positive Top-Line Results from Clinical Certification Study REMOVE with CATUVAB® to Enable Autologous Blood Transfusions in Cancer Surgeries – Biotech Investments

EQS-News: Lindis Blood Care GmbH / Key word(s): Study results/Study Lindis Blood Care Announces Positive Top-Line Results from Clinical Certification Study REMOVE with CATUVAB® to

April 23, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.